Quavonlimab

Summary

Quavonlimab (CHEMBL4650419) is a phase-3 clinical-stage antibody targeting CTLA4; indicated across 7 conditions including renal cell carcinoma and non-small cell lung carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Targets: 1 (CTLA4)
• Indications: 7 conditions
• Clinical trials: 12

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650419
Name	Quavonlimab
Type	Antibody
Max phase	3

Also known as: MK-1308, Quavonlimab, QUAVONLIMAB COMPONENT OF MK-1308A, QUAVONLIMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CTLA4	cytotoxic T-lymphocyte-associated protein 4 (CD152)	Binding	8.44	0%	P16410

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): CTLA4.

Top Reactome pathways

3 total, by targets touching each:

Pathway	Targets	Genes
Co-stimulation by CD28	1	CTLA4
Co-inhibition by CTLA4	1	CTLA4
RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)	1	CTLA4

Dominant GO biological processes

GO term	Targets
adaptive immune response	1
immune response	1
DNA damage response	1
negative regulation of B cell proliferation	1
negative regulation of T cell proliferation	1
positive regulation of apoptotic process	1
negative regulation of regulatory T cell differentiation	1
T cell receptor signaling pathway	1
B cell receptor signaling pathway	1
negative regulation of T cell receptor signaling pathway	1
negative regulation of T cell activation	1
immune system process	1
regulation of T cell proliferation	1

Indications & clinical

Indications

7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
renal cell carcinoma	3	MONDO:0005086	EFO:0000681
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
hepatocellular carcinoma	2	MONDO:0007256	EFO:0000182
colorectal neoplasm	2	MONDO:0005335	MONDO:0005575
neoplasm	1	MONDO:0005070	EFO:0000616
melanoma	1	MONDO:0005105	EFO:0000756
small cell lung carcinoma	1	MONDO:0008433	EFO:0000702

Clinical trials

Total trials: 12.

Phase distribution

Phase	Trials
PHASE1/PHASE2	7
PHASE2	3
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04736706	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
NCT05899049	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
NCT04626479	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
NCT04626518	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
NCT04895722	PHASE2	ACTIVE_NOT_RECRUITING	Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)
NCT04938817	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
NCT03179436	PHASE1/PHASE2	COMPLETED	Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)
NCT03516981	PHASE2	COMPLETED	A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
NCT04305041	PHASE1/PHASE2	COMPLETED	Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)
NCT04305054	PHASE1/PHASE2	COMPLETED	Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
NCT04700072	PHASE1/PHASE2	COMPLETED	Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)
NCT04740307	PHASE2	COMPLETED	Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).